| Reference : Genetic analysis of immunomodulating factors in sporadic Parkinson's disease. |
| Scientific journals : Article | |||
| Life sciences : Genetics & genetic processes | |||
| http://hdl.handle.net/10993/17119 | |||
| Genetic analysis of immunomodulating factors in sporadic Parkinson's disease. | |
| English | |
Krüger, Rejko  [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit] | |
| Hardt, C. [> >] | |
| Tschentscher, F. [> >] | |
| Jackel, S. [> >] | |
| Kuhn, W. [> >] | |
| Muller, T. [> >] | |
| Werner, J. [> >] | |
| Woitalla, D. [> >] | |
| Berg, D. [> >] | |
| Kuhnl, N. [> >] | |
| Fuchs, G. A. [> >] | |
| Santos, E. J. [> >] | |
| Przuntek, H. [> >] | |
| Epplen, J. T. [> >] | |
| Schols, L. [> >] | |
| Riess, O. [> >] | |
| 2000 | |
| Journal of Neural Transmission | |
| 107 | |
| 5 | |
| 553-62 | |
| Yes (verified by ORBilu) | |
| 0300-9564 | |
| AUSTRIA | |
| [en] Adjuvants, Immunologic/genetics ; Aged ; Alleles ; Antigens, CD/genetics ; Case-Control Studies ; Chi-Square Distribution ; Female ; Genotype ; Germany ; Humans ; Interleukin-6/genetics ; Male ; Middle Aged ; Parkinson Disease/genetics ; Polymorphism, Genetic/genetics ; Receptors, Tumor Necrosis Factor/genetics ; Receptors, Tumor Necrosis Factor, Type I ; Tumor Necrosis Factor-alpha/genetics | |
| [en] Immunomodulating factors have been shown to play a role in the pathogenesis of Parkinson's disease (PD) by biochemical methods. In order to investigate functionally important genes of the tumor necrosis factor alpha (TNFalpha) pathway we studied the frequency of DNA polymorphisms in the interleukin 6 (IL6), the TNFalpha, and the TNFalpha receptor 1 (TNFR1) genes in 264 sporadic German PD patients and in 183 age and sex matched German healthy controls. Analyzing the TNFalpha-308 polymorphism we found heterozygous individuals carrying alleles 1 and 2 more frequently in patients with a relative risk of 1.56 (p = 0.046, p(c) = 0.13, chi2 = 3.98). In contrast, the frequency of the B/2 haplotype described by the TNFR1-609 and TNFRI+36 polymorphisms was significantly decreased in our PD patients group (p = 0.0097, p(c) = 0.048, chi2 = 6.69) with a relative risk reduced to 0.52. Our results suggest an involvement of immunomodulating factors in the pathogenesis of sporadic PD as revealed by a molecular genetic approach. | |
| Luxembourg Centre for Systems Biomedicine (LCSB): Clinical & Experimental Neuroscience (Krüger Group) | |
| http://hdl.handle.net/10993/17119 |
There is no file associated with this reference.
All documents in ORBilu are protected by a user license.
